---
layout: post
title: "Prospective Grant of an Exclusive Patent License: Manufacture, Distribution, Sale and Use of T-Cell-Based Immunotherapies for Solid Tumors"
date: 2026-02-05 18:56:26 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2023-17256
original_published: 2023-08-11 00:00:00 +0000
significance: 8.00
---

# Prospective Grant of an Exclusive Patent License: Manufacture, Distribution, Sale and Use of T-Cell-Based Immunotherapies for Solid Tumors

**Published:** February 05, 2026 18:56 UTC
**Source:** Federal Register
**Original Published:** August 11, 2023 00:00 UTC
**Document Number:** 2023-17256

## Summary

The Eunice Kennedy Shriver National Institute of Child Health and Human Development and the National Cancer Institute, both institutes of the National Institutes of Health, Department of Health and Human Services, are contemplating the grant of an Exclusive Patent License to practice the inventions embodied in the Patents and Patent Applications listed in the Supplementary Information section of this Notice to EnZeta Immunotherapies, Inc. of the State of Delaware.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2023/08/11/2023-17256/prospective-grant-of-an-exclusive-patent-license-manufacture-distribution-sale-and-use-of)
- API: https://www.federalregister.gov/api/v1/documents/2023-17256

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
